» Articles » PMID: 26154005

Site-specific Conjugation Improves Therapeutic Index of Antibody Drug Conjugates with High Drug Loading

Citing Articles

Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.

Yang Q, Liu Y RSC Med Chem. 2024; 16(1):50-62.

PMID: 39568595 PMC: 11575643. DOI: 10.1039/d4md00637b.


Antibody drug conjugates in the clinic.

Udofa E, Sankholkar D, Mitragotri S, Zhao Z Bioeng Transl Med. 2024; 9(6):e10677.

PMID: 39545074 PMC: 11558205. DOI: 10.1002/btm2.10677.


Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity.

Aoyama M, Tada M, Yokoo H, Ito T, Misawa T, Demizu Y Bioconjug Chem. 2024; .

PMID: 39363433 PMC: 11488503. DOI: 10.1021/acs.bioconjchem.4c00348.


Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges.

Raja A, Kasana A, Verma V Mol Biotechnol. 2024; .

PMID: 39222285 DOI: 10.1007/s12033-024-01270-y.


Antibody-Drug Conjugates-Evolution and Perspectives.

Chis A, Dobrea C, Arseniu A, Frum A, Rus L, Cormos G Int J Mol Sci. 2024; 25(13).

PMID: 39000079 PMC: 11241239. DOI: 10.3390/ijms25136969.


References
1.
Chari R, Miller M, Widdison W . Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014; 53(15):3796-827. DOI: 10.1002/anie.201307628. View

2.
Alley S, Benjamin D, Jeffrey S, Okeley N, Meyer D, Sanderson R . Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008; 19(3):759-65. DOI: 10.1021/bc7004329. View

3.
Strop P, Liu S, Dorywalska M, Delaria K, Dushin R, Tran T . Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013; 20(2):161-7. DOI: 10.1016/j.chembiol.2013.01.010. View

4.
Hamblett K, Senter P, Chace D, Sun M, Lenox J, Cerveny C . Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004; 10(20):7063-70. DOI: 10.1158/1078-0432.CCR-04-0789. View

5.
Senter P, Sievers E . The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012; 30(7):631-7. DOI: 10.1038/nbt.2289. View